Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Oncolytics Biotech Inc.
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Relative Valuation== A comparable company analysis is undertaken using key metrics of Price-to-Book Ratio and EV/R&D Ratio, involving other companies operating in the biopharmaceutical sector, particularly those focusing on the development of oncology treatments. Note that Oncolytics anticipates profitability only upon commercial viability of Pelareorep, which renders usual comparing metrics like P/E ratio unavailable. {| class="wikitable" |+ ! ! colspan="5" |Market Data ($K) ! colspan="8" |Financial Data ($K) ! colspan="2" |Valuation (x) |- !Company !Ticker ! Price !Shares Out !Market Cap ! TEV !Revenue !EBITDA ! EBIT !Net Income !Assets !Liabilities !Book Value !R&D Exp. ! P/B ! EV/R&D |- |<u>Oncolytics Biotech Inc.</u> | <u>TSX:ONC</u> |<u>$2.78</u> |<u>65701</u> |<u>178090</u> |<u>156580</u> |<u>0</u> |<u>-20628</u> |<u>-20699</u> | <u>-19093</u> |<u>27585</u> | <u>8003</u> |<u>19582</u> |<u>11864</u> |<u>9.09x</u> |<u>13.20x</u> |- |TME Pharma |PAR:ALTME |$1.6 |5300 |8662 |8074 |0 |12551 |12028 |15910 |5620 |6327 | -707 |8148 | -12,25x |0.99x |- |Faron Pharmaceuticals |LON:FARN |$3.51 |66161 |231110 |237840 |0 | -28748 | -28892 | -30267 |12046 |24310 | -12265 |21822 | -18.84 |10.90x |- |Mustang Bio |NAS:MBIO |$5.00 |7281 |40400 |13780 |0 | -73436 | -76159 | -77525 |92422 |46149 |46273 |63949 |0.87x |0.22x |- |Celyad Oncology |BRU:CYAD |$0.60 |22594 |14660 |1590 |0 | -20597 | -21346 | -43125 |21071 |16457 |4614 |19923 |3.18x |0.08x |- |ESSA Pharma INC |(NasdaqCM:EPIX) |$2.85 |44.092 |125700 |31235 |0 |25875 |25996 |22473 |158500 |2166 |8933 |5121 |14.07x |6.09x |- |Helix BioPharma Corp. |(TSX:HBP) |$0.21 |200.019 |41004 |39674 |0 |4001 |4010 |3982 |1162 |493 |913 |4259 |44,91x |9.31x |} Below presents brief introduction to Oncolytic's peers; note by nature of the drug discovery industry, each company's focus and addressable market can vary. {| class="wikitable" |+ !Company !Description |- |TME Pharma |TME Pharma N.V. is a German biopharmaceutical company focused on developing proprietary cancer therapeutics, including their lead drug candidate, NOX-A12, for various cancer indications(such as metastatic pancreatic, colorectal, glioblastoma, and myeloma). They also have a collaboration with Merck Sharp & Dohme Corp. for studying NOX-A12 in combination therapy for metastatic pancreatic cancer. |- |Faron Pharmaceuticals |Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company that has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), being the comapny's lead asset, its investigative precision immunotherapy in phase I/II development, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. |- |Mustang Bio |Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating todayβs medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. |- |Celyad Oncology |Celyad Oncology is a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company is focusing on opportunities to support the development of next-generation CAR T-cell candidates in solid tumors and hematological malignancies. |- |ESSA Pharma INC |ESSA Pharma Inc. is a clinical stage pharmaceutical company and focuses on developing therapies for the treatment of prostate cancer. The company develops an oral drug candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. It has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. |- |Helix BioPharma Corp. |Helix BioPharma Corp., an immune-oncology company in Canada, is developing L-DOS47 and V-DOS47 for non-small cell lung cancer treatment. They have collaboration agreements with Moffitt Cancer Center to investigate pharmacodynamics, benefits of combination therapy, and with and University Hospital Tuebingen to assess therapeutic response in cancer models expressing CEACAM6. |} {| class="wikitable" |+ !Oncolytics Biotech Inc plc Valuation !Value |- |Implied Enterprise Value |156,580 |- |Implied Market Value |156,580 |- |Shares Outstanding |65,701 |- |Implied Value Per Share |2.38 |- |Average |2.51 |- |Current share price |2.78 |- |Difference |10.76% |}
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)